Industry Response Time Is Contributing To Slower Drug Approvals, FDA Says
Executive Summary
Industry response time is contributing to the increase in FDA drug approval times, Office of Review Management Special Assistant to the Director Kim Colangelo told the Regulatory Affairs Professionals Society's annual conference in Baltimore Nov. 7